1. Home
  2. EML vs CHRS Comparison

EML vs CHRS Comparison

Compare EML & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eastern Company (The)

EML

Eastern Company (The)

HOLD

Current Price

$20.18

Market Cap

130.2M

ML Signal

HOLD

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.36

Market Cap

186.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EML
CHRS
Founded
1858
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
130.2M
186.0M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
EML
CHRS
Price
$20.18
$1.36
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$4.51
AVG Volume (30 Days)
9.9K
1.0M
Earning Date
11-04-2025
11-06-2025
Dividend Yield
2.14%
N/A
EPS Growth
N/A
N/A
EPS
1.19
1.34
Revenue
$258,121,226.00
$277,728,000.00
Revenue This Year
$1.56
N/A
Revenue Next Year
$7.00
$67.29
P/E Ratio
$19.91
$1.01
Revenue Growth
N/A
152.07
52 Week Low
$18.49
$0.71
52 Week High
$30.72
$1.89

Technical Indicators

Market Signals
Indicator
EML
CHRS
Relative Strength Index (RSI) 52.19 51.56
Support Level $18.82 $1.18
Resistance Level $20.86 $1.35
Average True Range (ATR) 0.65 0.09
MACD 0.22 0.03
Stochastic Oscillator 67.85 67.35

Price Performance

Historical Comparison
EML
CHRS

About EML Eastern Company (The)

The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.

Share on Social Networks: